Introduction
Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic treatment for primary malignant diseases, and include myelodysplastic syndromes and acute myeloid leukemia (t-MDS/t-AML) 1 . The incidence of t-MN is rising commensurate with improvements in cancer treatments and increased survival. The prognosis for these patients has not improved substantially in several decades (median survival, 8 months); thus, t-MN is is an increasingly challenging clinical problem. Recurring chromosomal abnormalities correlate with prior treatment and clinical features of the disease 2,3 . For example, heterozygous deletions of the long arm of chromosome 5 [del(5q) ] are among the most common genetic abnormalities (~40%) in alkylator-induced t-MN, with a long latency period of 5-7 years, trilineage dysplasia, and a poor outcome. A del(5q) also occurs in 10-15% of patients with primary MDS, a subset of whom have MDS with an isolated del(5q) 4 , as well as in 15% of patients with AML de novo.
Using molecular mapping approaches, two minimally deleted regions have been identified: 5q31.2 in t-MN and MDS/AML, and 5q33.1 in MDS with an isolated del(5q) 1, 5, 6 .
Current studies support a haploinsufficiency model, in which loss of a single allele of more than one gene on 5q cooperate in the development of myeloid neoplasms. In fact, a number of genes and several miRNA sequences located on 5q, including APC, EGR1, CTNNA1, DIAPH1, HNRNPA0, HSPA9, RPS14, and miR-145/146, have been implicated in the development of myeloid disorders due to a gene dosage effect 1, 7, 8 . For example, RPS14 and miR-145/146 cooperate in the pathogenesis of MDS with an isolated del(5q) 6 . We demonstrated previously that EGR1 (5q31.2), which is deleted in all t-MN patients with a del(5q) and APC (5q22) which is deleted in >95% of patients, are both expressed at haploinsufficient levels, and inactivating For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From mutations have not been identified in the remaining alleles 9, 10 , confirming that these genes are not acting as typical tumor suppressor genes. Moreover, using mouse models, we showed that haploinsufficiency of Egr1 or Apc individually recapitulates some features of human MDS 8, 10 , further supporting their role in the pathogeneis of t-MN with a del(5q).
The early growth response 1 gene (EGR1) encodes a transcription factor that is a direct transcriptional regulator of many known tumor suppressor genes, including TP53, CDKN1A, (p21) and PTEN 11 , and it has been shown to play a role in maintaining hematopoietic stem cell (HSC) quiescence and retention in the bone marrow niche 12 . The adenomatous polyposis coli (APC) gene encodes a tumor suppressor protein best known for its involvement in the WNT signaling cascade via the regulation of β-catenin stability 13 ; loss of APC acutely activates WNT signaling 14, 15 . Activation of WNT signaling in the BM stromal niche plays a role in maintaining the HSC pool throughout life, and WNT signaling in leukemia stem cells is critical for their selfrenewal [16] [17] [18] . Of note, there is emerging evidence that a large percentage of MDS/AML patients with abnormalities of chromosomes 5 and/or 7 show constitutive activation of canonical WNT signaling in osteoblast stromal precursors 19 . Additional roles for APC include the regulation of mitosis, via control of spindle orientation and chromosome segregation, as well as cell migration 20 . In addition to the loss of 5q genes, the results of recent high-throughput sequencing studies have confirmed that loss of TP53 activity, through mutation or loss, is significantly associated with t-MN with a del(5q) 21, 22 . The well-characterized tumor suppressor gene, TP53, has been shown to play a role in cell cycle arrest, DNA repair, and apoptosis following cellular stress 23 , as well as maintenance of stem cell self-renewal 24, 25 .
We and others have previously established a role for reduced expression of EGR1, APC, or TP53 in the pathogenesis of myeloid diseases 8, 10, 25 . In this report, we modeled the For personal use only. on April 13, 2017. by guest www.bloodjournal.org From 6 simultaneous reduction in expression of all three genes in mice. We observed an accelerated development of macrocytic anemia in double and triple heterozygous (Apc del/+ ) mice that was reminiscent of the early stages of t-MN, suggesting that haploinsufficiency of APC cooperates with loss of EGR1 or TP53. We next examined whether this effect occurred entirely within the hematopoietic compartment (where deletion of 5q genes occur), and demonstrated that alterations within the stromal cell compartment due, in part, to deregulation of the Apc/WNT pathway, were largely responsible for the phenotype. Interestingly, we also demonstrated that exposure of the bone marrow microenvironment to ENU accelerates disease development in an Apc haploinsufficient background, raising awareness of the effects that alkylating agent therapy may have on the stromal microenvironment in patients.
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Methods

Mouse strains and transplantation studies
All studies were approved by the University of Chicago IACUC, and mice were housed in a fully-AALAC-accredited facility. Mx1-Cre − Apc fl/+ (Apc fl/+ ) and Mx1-Cre + Apc fl/+ (Apc del/+ ) mice were generated by crossing Apc fl/fl mice 26 with Mx1-Cre transgenic mice 27 . The efficiency of deletion in hematopoietic cells, after 3 intraperitoneal injections with 10mg/kg polyinosinicpolycytidylic acid (pI-pC) (GE Healthcare, Pittsburgh, PA) when mice were 2 mos. old, was verified by PCR, as previously described 10 . Conditional Apc mice, Egr1 knockout mice (provided by Dr Jeffrey Milbrandt), and Tp53 knockout mice (strain Trp53 tm1Tyi /J, developed in Tyler Jacks' laboratory) were all backcrossed onto the C57BL/6 (CD45.2) background. Egr1 +/-, Apc del/+ ; Tp53 +/-, Apc del/+ ; and Egr1 +/-, Tp53 +/-, Apc del/+ mice and corresponding Apc fl/+ controls were generated by crossing Mx1-Cre + Apc fl/fl mice with Egr1 +/and Tp53 +/mice.
CD45.1/CD45.2 WT mice were generated by crossing C57BL/6 (CD45.2) and B6.SJL (CD45.1).
Total BM cells (~5 x10 6 cells, of varying genotype indicated in individual figure legends) were transplanted, via retro-orbital injection, into lethally irradiated (8.6 Gy) Apc fl/+ or Apc del/+ mice that had been pre-treated, 3-4 weeks prior to irradiation, with pIpC to induce deletion. When Apc del/+ mice were used as donors, BM cells were harvested 3-4 weeks after pIpC. Mice were monitored daily and sacrificed either at ~3 mos. post pIpC ( Figure 4 ), or when they were moribund and/or severely anemic. ENU was administered at 100mg/kg either 1 month post pIpC ( Figure 5 ) or 2 weeks post pIpC in Apc recipient mice used for transplants ( Figure 7 ). Stromal cells were isolated from Apc fl/+ or Apc del/+ mice 4 weeks post pIpC, as described by Soleimani and Nadri 28 . For Apc del/del mice, cells were isolated 1 week post pIpC.
Peripheral blood analyses and histology
A complete blood count (CBC) from heart blood was determined with a Hemavet 950 counter (CDC Technologies, Oxford, CT, USA). All organs were recovered, fixed in 10% neutralbuffered formalin, embedded in paraffin, sectioned at 4-5 µm, and stained with hematoxylin and eosin for histological examination by a pathologist (JA). Peripheral blood, bone marrow aspirates, and spleen touch preparations were stained with Wright-Giemsa. Images were obtained using an Olympus microscope (Model BX51, Tokyo, Japan), equipped with an Optronics 3CCD 1080p digital camera (Goleta, CA), and processed with Adobe Photoshop (San Jose, CA).
Flow cytometric analysis
Single-cell suspensions of bone marrow and spleen were stained with fluorochrome-conjugated antibodies specific for CD71, Ter119, Gr-1, Mac-1 (CD11b), CD19, IgM, CD4, and CD8 and Annexin V (BD Biosciences, San Jose, CA). Flow cytometry was performed on a FACSCanto or LSRFortessa (BD Biosciences), and data were analyzed with the FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Statistical analysis
Survival times (time to sacrifice) were estimated by the Kaplan-Meier method and compared between groups via logrank tests. Blood counts were compared using pairwise two-sample t tests (Apc fl/+ vs. Apc del/+ ; Egr1 +/-, Apc fl/+ vs. Egr1 +/-, Apc del/+ ; etc).
Results
Loss of one allele of Egr1 and/or Tp53 accelerates Apc del/+ -induced fatal macrocytic anemia.
We hypothesized that loss of one copy of Egr1 may cooperate with Apc haploinsufficiency in the pathogenesis of anemia or other myeloid disorders, and that loss of Interestingly, Egr1 +/-, Apc del/+ mice developed disease significantly faster with a median survival of 179 versus 255 days (P < .0001); the control Egr1 +/-, Apc fl/+ mice remain healthy ( Figure 1A ).
In addition, Tp53 +/-, Apc del/+ mice had a significantly reduced median survival of 144 days versus 255 days. (P < .0001) ( Figure 1B ). To examine whether haploinsufficiency of Egr1 and Apc cooperate with reduced Tp53 function, we generated triple heterozygous mice ( Figure 1C ). Egr1 +/-, Tp53 +/-, Apc del/+ mice died at a significantly faster rate than Apc del/+ mice, with a median survival of 178 versus 255 days (P = .0002). However, there was no significant difference in the survival of the double or triple heterozygous mice (P = .66). In the absence of Apc haploinsufficiency, Egr1 +/-, Apc fl/+ ; Tp53 +/-, Apc fl/+ ; and Egr1 +/-, Tp53 +/-, Apc fl/+ control mice did not develop a macrocytic anemia, but some died of T lymphomas or soft tissue sarcomas at much later time points (>300 days). In summary, loss of one allele of Egr1, or Tp53, or both, equally accelerated the Apc del/+ -induced fatal anemia. In all of the anemic mice, the spleen was enlarged 3-10 fold suggestive of extramedullary erythropoiesis. The stages of erythroid development can be defined by the expression of CD71 and Ter119. In all anemic mice with Apc haploinsufficiency, there was an increased proportion of CD71 + Ter119 + erythroblasts and a decreased percentage of CD71 -Ter119 + mature erythroid cells ( Figure 3A ). Morphological and FACS analysis confirmed that this phenotype corresponded to a block at the basophilic erythroblast, or R2 (CD71 + Ter119 + ) stage ( Figure 2B , 3B). Histological analysis also revealed that there was an effacement of the normal architecture in the spleen, with an expansion of the red pulp ( Figure 2B ). Effacement of splenic white pulp was reflected by a decrease in the proportion of B and T lymphocytes. Thus, loss of one copy of 1 1 Egr1 and/or Tp53 accelerates the development of the macrocytic anemia in Apc del/+ mice; however, the phenotype of the mice appears identical at time of sacrifice, with a block at the early erythroblast stage leading to a fatal macrocytic anemia.
Erythropoietic block occurs more rapidly in double heterozygous mice and is not due to increased apoptosis.
To determine why the Egr1 +/-, Apc del/+ double heterozygous mice developed the fatal anemia at a significantly faster rate, we examined the kinetics of disease development by comparing the phenotype of mice at three months post pIpC treatment (Apc deletion). A comparison of the CBC values shows that early signs of a macrocytic anemia were more pronounced in double heterozygous mice, as the RBC, Hb, and hemocrit counts were lower, and MCV and RDW were slightly increased ( Figure 4A ). We next compared the stages of erythropoiesis. When Ter119 high cells are analyzed using both the CD71 and FSC parameters, they consistently resolve into 3 principal populations: Ery.A cells (Ter119 high CD71 high FSC high ) are basophilic erythroblasts, and Ery.B cells (Ter119 high CD71 high FSC low ) are late basophilic and polychromatic erythroblasts, whereas Ery.C cells (Ter119 high CD71 low FSC low ) are orthochromatic erythroblasts and reticulocytes. We found that at three months post Apc deletion, the ratio of the Ery.A versus Ery.C population was significantly higher in the double heterozygous mice (Egr1 +/-, Apc del/+ ) than in Apc del/+ and control mice, suggesting that ineffective erythropoiesis develops more rapidly in the double heterozygous mice ( Figure 4B ). To compensate for the loss of mature erythroid cells, the number of erythroid colony-forming units (CFU-Es) in spleen is increased in both the Apc del/+ and Egr1 +/-, Apc del/+ mice (Supplemental Figure S1 ). In other mouse models (e.g., Stat5a/b -/-), decreased survival of early erythroblasts accounts for the block in For personal use only. on April 13, 2017. by guest www.bloodjournal.org From differentiation 29, 30 . We measured the percentage of Annexin V + cells in the CD71 + Ter119 + (R2) population in the spleen, and consistently observed decreased apoptosis in both the Apc del/+ and Egr1 +/-, Apc del/+ mice, suggesting that the block in differentiation was not due to decreased survival of erythroblasts ( Figure 4C ). A similar phenotype was observed in Tp53 +/-, Apc del/+ mice (Supplemental Figure S2) . Although Egr1 and Tp53 expression induces apoptosis in tumor cells 31 , a reduction in the dosage of Egr1 or Tp53 did not significantly decrease apoptosis in the Apc haploinsufficient background. Thus, the kinetics of disease development appear to be due to a block in early erythroid differentiation that occurs more rapidly in double heterozygous mice, but is not associated with an increase in apoptosis.
ENU accelerates Apc del/+ -induced macrocytic anemia.
t-MN with a del(5q) is associated with prior exposure to alkylating agents and mutations of Tp53 3,21 . We previously showed that loss of one copy of the del(5q) gene, Egr1, cooperates with secondary mutations, induced by the alkylating agent ENU, resulting in a myeloproliferative disease with ineffective erythropoiesis in mice 8 . To examine the interaction of Apc, Egr1, and Tp53 and the impact of cooperating mutations, we treated mice with haploinsufficient levels of Apc, Egr1, and Tp53 with ENU. ENU equally accelerated the For personal use only. on April 13, 2017. by guest www.bloodjournal.org From mice (Egr1 +/-, Tp53 +/-, Apc del/+ ) also accelerated anemia development (median survival was 97 d versus 178 d, P < .0001), and did not appear to alter the phenotype.
To examine why ENU-treated mouse cohorts with Apc haploinsufficiency died of a rapid and fatal anemia, we initially evaluated the hematological parameters. The RBC and Hb count were significantly decreased and the MCV and RDW was significantly increased in all ENUtreated mouse cohorts with Apc haploinsufficiency compared to Apc fl/+ (Apc-WT) controls bled at a similar time point ( Figure 5B ). There was also a significantly increased monocyte count, consistent with the development of monocytosis. There were 2/15 Egr1 +/-, Tp53 +/-, Apc del/+ and 1/16 Egr1 +/-, Apc del/+ mice that developed a T lymphoma in addition to the anemia. All ENUtreated Apc del/+ cohorts displayed splenomegaly with a decreased percentage of CD71 -Ter119 + mature erythroid cells, and an increased proportion of CD71 + Ter119 + erythroblasts, corresponding to a block at the basophilic erythroblast stage (Supplemental Figure S3 ). These data suggest that all ENU-treated, Apc del/+ cohorts develop a macrocytic anemia with monocytosis that is similar to non-ENU treated, Apc del/+ cohorts; however, they develop this phenotype at an accelerated pace, regardless of the loss of Egr1 or Tp53 expression.
Apc del/+ -induced fatal anemia is cell extrinsic.
Studies with the Apc min mice have suggested that cell extrinsic factors may contribute to the development of myeloid disease 32 . To determine whether the fatal anemia in Apc del/+ mice was cell intrinsic, we transplanted WT; Egr1 +/-; Tp53 +/-, Apc del/+ ; or Egr1 +/-, Apc del/+ BM into lethally irradiated Apc del/+ recipients or Apc fl/+ control recipients that are WT for Apc. Figure S4 ). We confirmed that altered hematopoiesis occurred in donor cells, as Apc del/+ recipient hematopoietic stem and progenitor cells are not present in recipient mice after transplantation of CD45.1/CD45.2 WT donor BM cells into Apc del/+ (CD45.2) recipients ( Figure 6B ). We also showed by PCR that the splenocytes isolated from anemic recipients were donor-derived and WT for Apc, as anticipated ( Figure 6C ). Together, this suggests that the fatal macrocytic anemia is induced by an Apc-haploinsufficient BM microenvironment. Supporting this conclusion, we confirmed that stromal cells isolated from Apc del/+ mice undergo deletion of one Apc allele ( Figure 6D ). Our initial studies support a relationship between Apc dose and β-catenin levels in stroma. Whereas in splenic cells we observed β-catenin protein expression following deletion of both Apc alleles, but not following haploinsufficient loss of Apc (i.e., only in Apc del/del cells), we observed a moderate (~1.8-fold ) and a strong (~9 fold) increase in β-catenin protein expression in Apc del/+ and Apc del/del stromal cells, respectively ( Figure 6E ).
Transplantation of bone marrow cells into
Similar to Apc del/+ mice, all Apc del/+ recipient mice developed a fatal macrocytic anemia, with an arrest of erythroid maturation at the CD71 + Ter119 + (R2) stage (Supplemental Figure S5 ).
Lethally-irradiated Apc del/+ recipient mice transplanted with Apc del/+ BM developed the anemia at a significantly accelerated rate compared to Apc del/+ mice (median survival of 130 d vs. 255 d, P < .0001, comparing Figure 1 and 6 ), suggesting that alterations of the microenvironment following irradiation accelerated the anemic phenotype. There were two exceptions to the macrocytic anemia phenotype: one Apc del/+ recipient that received Tp53 +/donor cells developed an immature lymphoid leukemia with an infiltration of blasts into the liver and lymph node, and another that received Egr1 +/donor cells developed a myeloproliferative disorder with an For personal use only. on April 13, 2017. by guest www.bloodjournal.org From expansion of immature myeloid cells in the spleen (Supplemental Figure S6 ). This suggests that an Apc haploinsufficient microenvironment may be conducive to developing other hematological diseases, in addition to a fatal macrocytic anemia.
Effect of ENU on the BM microenvironment.
Given that ENU rapidly accelerated the onset of anemia, regardless of Egr1 or Tp53 expression, and that Apc del/+ -induced anemia was accelerated by transplantation into a lethally irradiated Apc haploinsufficient microenvironment, we considered the possibility that alkylating agent therapy and/or radiation may influence early disease progression through alterations to the bone marrow stroma. To examine this possibility more closely, we transplanted CD45.1/CD45.2 WT BM cells into lethally irradiated Apc mice (CD45.2) that had been pretreated with both ENU (to induce mutations) and pIpC (to induce Apc deletion in Apc del/+ , but not Apc fl/+ , Crecontrol mice) ( Figure 7) . Interestingly, exposing Apc del/+ recipients to ENU significantly accelerated the development of the fatal anemia. Median survival was 84 days for ENU-treated Apc del/+ recipients, versus 101 d for non-ENU treated Apc del/+ recipients (P = .014). In contrast, only 1 in 5 Apc fl/+ (WT) recipients exposed to ENU developed a T cell lymphoma (at 145 d) within the timeframe examined (~224 d). The accelerated rate of disease development in ENU-treated recipient mice was also observed when Tp53 +/donor BM cells were used (112 d for ENUtreated vs. 141 d for non-ENU treated recipients, P = .011) (Supplemental Figure S7 ). To date, none of the ENU-treated Apc fl/+ (WT) recipients of Tp53 +/-BM cells have developed disease (at 196 d). Together, these results suggest that exposure of the microenvironment to an alkylating agent increases the pace of disease development, in an Apc haploinsufficient recipient background, and is not influenced by donor cell genotype, under these experimental conditions.
Discussion
Therapy-related myeloid neoplasia is a complex disease; in ~40% of cases, the disease involves loss of genetic material from the long arm of one chromosome 5 homolog, presumably leading to the disruption of multiple signaling networks. A prevalent hypothesis is that chemotherapy and/or radiation treatment, administered for the primary malignant disease, promotes the acquisition of recurring chromosomal abnormalities, such as del(5q) or -7/del(7q), in hematopoietic stem cells, ultimately leading to acquisition of cooperating mutations, such as TP53 mutations, and resulting in the expansion of clonal populations. In addition to the loss of 5q genes in hematopoietic stem and progenitor cells, emerging evidence in MDS and AML with myelodysplasia-related changes suggests that a permissive BM microenvironment, may be required for frank malignancy to develop 33 . For example, in patients with MDS with a del(5q), the beneficial effects of lenalidomide is associated with a substantial improvement of the hematopoietic supporting potential of the bone marrow stroma 34 . In this paper, we developed a genetically modified mouse model recapitulating some of the molecular defects that we hypothesize are key to the development of t-MN with a del(5q), namely haploinsufficiency of EGR1, APC, and TP53.
Apc haploinsufficient mice manifest a number of features of the early stages of t-MN, including anemia characterized by anisopoikilocytosis, macrocytosis, and an increased MCV 10 .
Herein, we demonstrated that Apc haploinsufficiency in mice, combined with Egr1 and/or Tp53 haploinsufficiency accelerated disease development without altering disease phenotype. These results suggest that loss of one copy of Egr1 or Tp53 functioned as an enhancer of the Apc haploinsufficient phenotype, possibly by introducing cross-talk with additional signaling pathways or enhancing a common pathway. Interestingly, the disease was not further Tp53 may act redundantly, possibly eliciting similar molecular pathways, at least with respect to the anemia phenotype in this mouse model.
Although our genetic crosses of Egr1, Apc, and Tp53 triple heterozygous mice demonstrated cooperation between pathways induced by haploinsufficient expression, they did not address whether cooperation was occurring only within hematopoietic cells, in which loss of 5q genes is known to occur in t-MN patients. We were also interested in the effects on nonhematopoietic cells, as emerging evidence suggests that the BM microenvironment plays a crucial role in the development of myeloid neoplasms. For example, the results of characterization of Apc min mice have suggested that haploinsufficient loss of Apc may alter the BM microenvironment and contribute to the MDS phenotype 32 . To determine whether the observed cooperation between Egr1 and Apc, or Tp53 and Apc, occurred within hematopoietic or progenitor cells vs. bone marrow stromal cells, or resulted from a cooperation between these components of the bone marrow niche, we performed transplantation studies. Regardless of the genotype of the donor cells, the Apc del/+ recipients developed a fatal macrocytic anemia at a significantly faster rate than did the conditional Apc del/+ mice (P < .0001). We speculate that irradiation of recipient mice may have been responsible for the faster rate of anemia development, as ionizing radiation induces multiple changes in the BM stromal cell compartment [35] [36] [37] . For example, irradiated mesenchymal stromal cells have a high DNA doublestrand break repair capacity, allowing them to survive radiation treatment and produce factors such as TNFα, TGFβ and IL-6, cytokines known to influence the development of MDS and AML 38, 39 .
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Since MDS patients with a del(5q) have loss of EGR1 and APC in hematopoietic cells, we also tested whether transplantation of Apc del/+ or Egr +/-, Apc del/+ bone marrow cells into wildtype recipients (Apc fl/+ ) caused a deleterious phenotype; however, none of these mice showed defects in erythropoiesis or red blood cell production or other hematopoietic defects (Supplementary Figure S5) . This suggests that the effects we observed were predominantly due to deregulation of Apc expression in the BM microenvironment. At first glance, the link between our mouse model and t-MN may not be apparent, as there is no strong evidence that del(5q) genes are deleted in mesenchymal stromal cells in patients. However, there is emerging evidence that WNT signaling, of which APC is a major regulator, is disrupted in bone marrow stromal cells from patients with MDS or AML. Kode et al., showed that 15 of 53 patients with MDS or AML, chosen at random, showed nuclear localization of β -catenin in stromal osteoblasts. Of note, 12 of these 15 patients (80%) had abnormalities of chromosomes 5 and/or 7, characteristic features of the largest genetic subgroup of t-MN patients 19 . Consistent with the hypothesis that aberrant WNT signaling in the BM microenvironment may play a role in MDS progression, we observed an Apc dose-dependent accumulation of β-catenin in stromal cells isolated from Apc haploinsufficient or null mice ( Figure 6E ).
A seminal finding in our study points to the potential deleterious effects of cytotoxic therapy, particularly alkylating agents, on the bone marrow microenvironment of patients who develop t-MN. First, we noted a rapid acceleration of the disease phenotype in ENU-treated, conditional Apc haploinsufficient mice, regardless of the germline loss of Egr1 or Tp53 in HSCs and bone marrow stromal cells ( Figure 5 ). Second, transplantation of bone marrow cells from these ENU-treated Apc del/+ mice engrafted WT recipients, but did not result in disease up to 260 days post transplant (data not shown). Third, we showed that exposure of the bone marrow
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From microenvironment to ENU increased the pace of macrocytic anemia development in an Apc haploinsufficient, but not a WT, background (Figure 7, Supplementary Figure S7 ). Together, our data and the literature supports the hypothesis that radiation and/or chemotherapy that t-MN patients receive for their primary malignant disease leads to a deregulation of signaling networks within the BM microenvironment, possibly through a deregulation of the WNT pathway.
In the context of this current mouse model, the impact of Egr1 and Tp53 haploinsufficiency on the hematopoietic cells, stromal cells, or both is more complex. At first glance, the transplantation data supports the hypothesis that loss of Egr1 or Tp53 in the stromal cells is enhancing the effects of Apc haploinsufficiency within the microenvironment. However, it is equally plausible that the effects of radiation, needed for the transplantation process, in itself has particularly strong effects on an Apc haploinsufficient microenvironment that masks a more subtle cooperation between Egr1 +/or Tp53 +/in hematopoietic cells with Apc haploinsufficiency in stromal cells. An additional possibility, that we cannot rule out at this time, is a cooperation between loss of Egr1, Tp53, and Apc in hematopoietic cells. In this regard, we have found that knock-down of Tp53 (using a shRNA) in Egr1, Apc double heterozygous hematopoietic cells, when transplanted into a WT background, leads to a low frequency of myeloid leukemia (data not shown). In summary, our data point to the importance of considering the effects that radiation and/or alkylating agent therapy has not only on the hematopoietic cells, but on the microenvironment as well, and the potential that loss of genetic material in the hematopoietic cells, and disruption of key signaling pathways within the bone marrow niche synergize in the pathogenesis or progression of myeloid diseases. 
